ClinicalTrials.gg
CompletedNCT06100900Updated Jan 8, 2025

Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 1 interventional study of BCX10013 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by BioCryst Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by BioCryst Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with PNH. Approximately 8 participants will be enrolled in this study. Participants may receive treatment for up to 52 weeks.

02

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • Paroxysmal Nocturnal Hemoglobinuria
  • Factor D
  • complement inhibitor
  • alternative pathway inhibitor
  • BioCryst
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's enrollment of 8 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

BioCryst Pharmaceuticals is the lead sponsor of 54 studies on the registry; 1 is open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or non-pregnant, non-lactating female adults ≥ 18 years old.
  2. Documented diagnosis of PNH confirmed by flow cytometry.
  3. (BMI) ≤ 40 kg/m\^2.
  4. Are either: (a) naïve to treatment with a complement inhibitor; or (b) have received no treatment with ravulizumab for at least 12 months prior to the screening visit and have received no treatment with eculizumab or pegcetacoplan for 6 months prior to the screening visit.
  5. Documentation of current vaccinations against N. meningitidis, S. pneumoniae, and H. influenzae type B [Hib] or willingness to start vaccination series at least 14 days prior to Day 1.

Key Exclusion Criteria:

  1. Known history of or existing diagnosis of hereditary complement deficiency.
  2. History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation during the study.
  3. Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled cardiovascular or cerebrovascular condition, including unstable angina, severe congestive heart failure, unexplained syncope, arrhythmia, and critical aortic stenosis.
  4. History of within 5 years prior to the screening visit.
  5. Treatment with anti-thymocyte globulin within 180 days prior to the screening visit.
  6. Initiation of treatment with an erythropoiesis-stimulating agent (eg, erythropoietin), a thrombopoietin receptor agonist (eg, eltrombopag), or danazol within 28 days prior to the screening visit.
  7. Receiving iron with an unstable dose (ie, increasing or decreasing) in the 28 days prior to the screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    BCX10013

    Participants with PNH will receive BCX10013 daily for 4 weeks before dose escalation may occur.

    Drug: BCX10013

Interventions

  • DrugBCX10013

    Multiple dose levels may be tested in this study.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Graded Laboratory Abnormalities, and Changes From Baseline (CFB) in Laboratory Analytes, Vital signs, Electrocardiograms (ECGs), and Physical Examination Findings.

    Time frame: up to 52 weeks

Secondary outcomes

  1. CFB in Lactate Dehydrogenase

    Time frame: Baseline, Week 52

  2. CFB in the Ratio of Total PNH Red Blood Cell Clone Size to PNH White Blood Cell Clone Size

    Time frame: Baseline, Week 52

  3. CFB in Hemoglobin

    Time frame: Baseline, Week 52

  4. Percentage of Participants who are Transfusion-free

    Time frame: 52 weeks

  5. Percentage of Participants Achieving a Within-subject Clinically Meaningful CFB in the FACIT-Fatigue scale

    Time frame: 52 weeks

  6. CFB in Other Clinical Biomarkers of PNH Disease Activity including absolute reticulocyte count, total PNH red blood cell clone size, haptoglobin levels, total bilirubin, and aspartate transaminase

    Time frame: Baseline, Week 52

  7. Number of Participants with Clinical PNH Symptoms

    Time frame: up to 52 weeks

  8. Concentration of BCX10013 and its Metabolite(s) in Plasma

    Time frame: Pre-dose, 0.5, 1, 2, 4, and 6 hours post dose on Day 1, Week 2, and Week 4

  9. Concentration of BCX10013 and its Metabolite(s) in Urine (if applicable)

    Time frame: Pre-dose and all urine from 0 to 6 hours post dose on Day 1, Week 2, and Week 4

07

Study locations

4 sites
  • BioCryst Investigative Site
    Ampang, Malaysia
  • BioCryst Investigative Site
    Bloemfontein, South Africa
  • BioCryst Investigative Site
    Cape Town, South Africa
  • BioCryst Investigative Site
    Pretoria, South Africa
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Dec 2024, 13 months.

Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 25, 2023
StartActual
Oct 24, 2023
Primary completionActual
Dec 11, 2024
CompletionActual
Dec 11, 2024
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100900
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Oct 24, 2023
Primary completion
Dec 11, 2024
Completion
Dec 11, 2024
Last update
Jan 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion